Shandong Provincial Hospital

Running trials

• Recruiting

  Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy

  NCT07789184· Phase 3· Hua Huang, MD, PhD· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

  NCT07541170· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis

  NCT07406035· Phase 2· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source

• Recruiting

  Non-stenting Treatment Strategy for Acute Myocardial Infarction With Non-severe Stenosis(EROSION IV)

  NCT07567625· Harbin Medical University· Source

• Recruiting

  The Efficacy and Safety of Inpegsomatropin Injection in Children With Turner Syndrome (TS) and Short Stature

  NCT07614152· Phase 3· Xiamen Amoytop Biotech Co., Ltd.· Source

• Enrolling by invitation

  Research Study to Examine Blood Sugar Control, Treatment Satisfaction and Adherence in People With Type 2 Diabetes After Switching From Daily Basal Insulin to Once-weekly Insulin Icodec

  NCT07658417· Novo Nordisk A/S· Source

• Recruiting

  A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

  NCT07477587· Phase 1· Shanghai Henlius Biotech· Source

• Recruiting

  Single vs. Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Intervention With DCB-only Strategy (KONG-FREEDOM-I)

  NCT07587099· Gan Lijun· Source

• Recruiting

  SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer

  NCT07256236· Phase 2· Fujian Cancer Hospital· Source

• Recruiting

  A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

  NCT07277231· Phase 3· BeOne Medicines· Source

• Recruiting

  A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer

  NCT07347600· Hoffmann-La Roche· Source

• Not yet recruiting

  A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)

  NCT07365371· Phase 4· Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine· Source

• Recruiting

  JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.

  NCT07284134· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source

• Recruiting

  BDB-001 Phase III Trial in ANCA-Associated Vasculitis

  NCT07168161· Phase 3· Staidson (Beijing) Biopharmaceuticals Co., Ltd· Source

• Recruiting

  CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  NCT07207811· Phase 3· Novo Nordisk A/S· Source

• Not yet recruiting

  A Phase 3 Study of HS-20094 in Patients With T2DM

  NCT07156539· Phase 3· Jiangsu Hansoh Pharmaceutical Co., Ltd.· Source

• Recruiting

  Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

  NCT06757634· Phase 3· Celcuity Inc· Source

• Recruiting

  A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

  NCT07292714· Phase 2· Mabwell (Shanghai) Bioscience Co., Ltd.· Source

• Recruiting

  A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy

  NCT07010263· Phase 3· Akeso· Source

• Recruiting

  A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

  NCT06943872· Phase 3· BeOne Medicines· Source

• Recruiting

  Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy

  NCT06862869· Hoffmann-La Roche· Source

• Recruiting

  Clinical Study on the Efficacy and Safety of TNTL in the Treatment of Non-proliferative Diabetic Retinopathy

  NCT06817265· Phase 3· Beletalent (Zhuhai) Pharmaceutical Co., Ltd· Source

• Recruiting

  A Multicenter Randomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL1706) Combined With SOX Chemotherapy Versus Chemotherapy Alone in the Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

  NCT06829797· Phase 2· Shandong Provincial Hospital· Source

• Recruiting

  Improve the Strategies of Endoscopic and Interventional Treatment of Gastroesophageal Hemorrhage in Portal Hypertension

  NCT06970509· Shanghai Zhongshan Hospital· Source

• Not yet recruiting

  A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases

  NCT06774664· Phase 1/2· Sinocelltech Ltd.· Source

• Recruiting

  Clinical Study of Low-dose Interval Radiotherapy Combined With Tirelizumab and SOX Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

  NCT06766578· Phase 2· Shandong Provincial Hospital· Source

• Active, not recruiting

  Nipocalimab in Moderate to Severe Sjogren's Disease

  NCT06741969· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06711900· Phase 3· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Source

• Recruiting

  A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

  NCT06629779· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

  NCT06550076· Phase 3· Takeda· Source

• Active, not recruiting

  Efficacy and Safety of Colchicine After PCI

  NCT06472908· Phase 3· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Source

• Active, not recruiting

  A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT06448312· Phase 3· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Source

• Recruiting

  A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL

  NCT06363994· Phase 3· InnoCare Pharma Inc.· Source

• Recruiting

  ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)

  NCT06378138· Phase 2/3· Beijing InnoCare Pharma Tech Co., Ltd.· Source

• Recruiting

  Preventive Drug-coated Balloon Angioplasty in Vulnerable Atherosclerotic Plaque (RESTORE Trial)

  NCT06365502· Harbin Medical University· Source

• Recruiting

  Goal-directed Enteral Nutritional Perioperative Management

  NCT06510543· Cancer Institute and Hospital, Chinese Academy of Medical Sciences· Source

• Recruiting

  Multicenter Prospective Cohort Study of Twin Maternal-Child Dyads in China

  NCT06414655· Peking University Third Hospital· Source

• Recruiting

  A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients

  NCT06155084· Phase 1/2· Hinova Pharmaceuticals Inc.· Source

• Active, not recruiting

  Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

  NCT06073821· Phase 3· BeOne Medicines· Source

• Recruiting

  Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

  NCT06057402· Phase 4· Pfizer· Source

• Recruiting

  An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease

  NCT05908695· Phase 4· Green Valley (Shanghai) Pharmaceuticals Co., Ltd.· Source

• Active, not recruiting

  A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

  NCT05884398· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Lobectomy-First vs. Lymphadenectomy-First for Operable NSCLC (LOFTY)

  NCT06577792· Sun Yat-sen University· Source

• Active, not recruiting

  Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)

  NCT06009861· Phase 2· Peking University Hospital of Stomatology· Source

• Recruiting

  Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture

  NCT05866029· Peking Union Medical College Hospital· Source

• Active, not recruiting

  A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC

  NCT06443684· Shanghai Chest Hospital· Source

• Active, not recruiting

  A Study of Telitacicept for IgA Nephropathy (TELIGAN)

  NCT05799287· Phase 3· RemeGen Co., Ltd.· Source

• Active, not recruiting

  Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC

  NCT05765825· Phase 2· Sichuan University· Source

• Active, not recruiting

  Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis

  NCT05486104· Phase 2· Ganzhou Hemay Pharmaceutical Co., Ltd· Source

• Active, not recruiting

  Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  NCT05479994· Phase 2· BeiGene· Source

Showing 50 of 66.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Gastric and oesophageal cancer5 recruiting
• Alzheimer disease3 recruiting
• Chronic lymphocytic leukaemia3 recruiting
• Coronary artery disease3 recruiting
• Lung cancer3 recruiting
• Metastatic breast cancer3 recruiting
• Colorectal cancer2 recruiting
• Multiple myeloma2 recruiting
• Prostate cancer2 recruiting
• Type 2 diabetes2 recruiting
• Amyloidosis1 recruiting
• ANCA-associated vasculitis1 recruiting
• Cervical cancer1 recruiting
• COPD1 recruiting
• Diabetic eye disease1 recruiting
• Heart failure1 recruiting
• High blood pressure1 recruiting
• IgA nephropathy1 recruiting
• Macular degeneration1 recruiting
• Mantle cell lymphoma1 recruiting
• Migraine1 recruiting
• Obesity1 recruiting
• Osteoporosis1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Sarcoma1 recruiting
• Thyroid cancer1 recruiting
• Turner syndrome1 recruiting
• Vascular dementia1 recruiting

Closed trials

• Completed

  HPP737 in Adult Patients With Plaque Psoriasis

  NCT07712731· Phase 3· Newsoara Biopharma Co., Ltd.· Source

• Completed

  Phase IIa Study for IPG11406 in Patients With Lupus Nephritis

  NCT06717815· Phase 1/2· Nanjing Immunophage Biotech Co., Ltd· Source

• Completed

  Impact of Congenital Heart Disease on the Prognosis of Childhood Hematological Neoplasms: A Multicenter Cohort Study

  NCT07249138· Children's Hospital of Fudan University· Source

• Completed

  A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease

  NCT06522997· Phase 2· Bayer· Source

• Completed

  An Observational Study to Assess Real-World Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in China

  NCT06421740· AbbVie· Source

• Completed

  A Clinical Study of JS005 in Patients With Ankylosing Spondylitis

  NCT06250062· Phase 2· Shanghai Junshi Bioscience Co., Ltd.· Source

• Completed

  A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

  NCT06088043· Phase 3· Takeda· Source

• Completed

  A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets

  NCT06024915· Phase 1· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Completed

  Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects

  NCT05966272· Phase 2· Fujian Shengdi Pharmaceutical Co., Ltd.· Source

• Terminated

  A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

  NCT05828589· Phase 1· BeOne Medicines· Source

• Completed

  HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis.

  NCT07712705· Phase 3· Newsoara Biopharma Co., Ltd.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome

  NCT05673993· Phase 3· RemeGen Co., Ltd.· Source

• Completed

  TESTING -ON Post-Trial ObservatioNal Cohort Study

  NCT05434325· The George Institute· Source

• Completed

  Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate

  NCT05590793· Phase 3· Ipsen· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture

  NCT05352516· Phase 3· Shanghai Henlius Biotech· Source

• Completed

  Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)

  NCT05298423· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease

  NCT04974749· Phase 3· Takeda· Source

• Completed

  A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma

  NCT05051891· Phase 3· Beijing InnoCare Pharma Tech Co., Ltd.· Source

• Completed

  A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

  NCT05228470· Phase 2· Pfizer· Source

• Terminated

  Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

  NCT04968184· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study of Vedolizumab in Adults in Real-World Practice

  NCT04872491· Takeda· Source

• Completed

  GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer

  NCT05054751· Phase 3· Genor Biopharma Co., Ltd.· Source

• Completed

  Comparison Between Upgraded '2C3L' vs. PVI Approach for Catheter Ablation of Persistent Atrial Fibrillation

  NCT04497376· Beijing Anzhen Hospital· Source

• Completed

  A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

  NCT04939142· Phase 3· Antengene Corporation· Source

• Completed

  Zanubrutinib in Participants With Active Proliferative Lupus Nephritis

  NCT04643470· Phase 2· BeiGene· Source

• Completed

  Study on AI Recognition System Of Heart Sound In Congenital Heart Disease Screening

  NCT04307030· Xinhua Hospital, Shanghai Jiao Tong University School of Medicine· Source

• Completed

  The Effect of the Number of Central Lymph Nodes on Changes in Parathyroid Function

  NCT06432244· Shandong Provincial Hospital· Source

• Completed

  The Effect of the Application of Head Mounted Magnifying Glasses on Postoperative PTH Changes in Thyroid Surgery

  NCT06432257· Shandong Provincial Hospital· Source

• Completed

  A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT03524092· Phase 3· Eli Lilly and Company· Source

• Completed

  An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

  NCT03518086· Phase 3· Eli Lilly and Company· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Liver and biliary tract cancer78 works · 0 trials
• Gastric and oesophageal cancer58 works · 6 trials
• Glioblastoma27 works · 0 trials
• Hearing loss23 works · 0 trials
• Endometriosis12 works · 0 trials
• Immune thrombocytopenia (ITP)12 works · 0 trials
• Myocarditis11 works · 0 trials
• Aortic aneurysm10 works · 0 trials
• Liver cirrhosis6 works · 0 trials
• Trigeminal neuralgia6 works · 0 trials
• Fabry disease5 works · 1 trial
• Vascular dementia4 works · 1 trial
• Pompe disease3 works · 0 trials